Robert E. Reiter

Robert Reiter is Director of the Prostate Cancer Program at UCLA's Jonsson Comprehensive Cancer Center and a leading figure in the molecular biology of prostate cancer, with particular expertise in androgen receptor biology, AR splice variants, and the identification of novel therapeutic targets. His laboratory identified and characterized prostate stem cell antigen (PSCA), a cell-surface glycoprotein overexpressed in prostate cancer, and has been a pioneer in exploiting cancer-specific surface antigens for targeted delivery of therapeutics including antibody-drug conjugates and CAR-T cells. Reiter's most widely known contribution to CRPC biology is his work on androgen receptor splice variants, particularly AR-V7 — a constitutively active AR isoform lacking the ligand-binding domain that is generated by alternative splicing and is a major driver of enzalutamide and abiraterone resistance. His laboratory, along with work from the Bhatt and Antonarakis groups, defined the biology of AR-V7, characterized its mechanisms of generation and regulation, and developed assays for its clinical detection. Understanding AR-V7 has been transformative for prostate cancer therapy, providing the first actionable resistance biomarker and a therapeutic target for next-generation AR inhibitors targeting the N-terminal domain. Beyond AR biology, Reiter's laboratory has made important contributions to understanding prostate cancer stem cells and their role in treatment resistance and tumor regeneration after hormonal therapy. His group has characterized the molecular identity of prostate cancer stem-like cells, their relationship to luminal and basal epithelial lineages, and their resistance to AR-targeted agents — work with significant implications for designing therapies to eradicate minimal residual disease and prevent castration-resistant recurrence. His dual expertise in translational biology and prostate cancer surgery gives him a distinctive perspective on bench-to-bedside translation.

Robert Reiter 是 UCLA 强森综合癌症中心前列腺癌项目主任，在雄激素受体生物学、AR 剪接变体和新型治疗靶点鉴定方面有深厚专长。他的实验室鉴定和表征了前列腺干细胞抗原（PSCA），并在 AR-V7（一种构成性活化的 AR 异构体，是恩扎鲁胺和阿比特龙耐药的主要驱动因素）的生物学研究中做出了开创性贡献。 Reiter 还在前列腺癌干细胞和治疗耐药方面做出了重要贡献，其研究对于设计消除微小残留病灶和预防去势抵抗性复发的治疗方案具有重要意义。